The US Food and Drug Administration (FDA) has accepted Enzychem Lifesciences’ investigational new drug (IND) application to assess EC-18 in a Phase II clinical trial in Covid-19 patients.

The trial will enrol patients with acute respiratory disease syndrome (ARDS). A Phase II trial of EC-18 to prevent Covid-19-related ARDS is ongoing in South Korea.

During the multi-centre, randomised, double-blind, placebo-controlled Phase II trial in the US, EC-18’s safety and efficacy will be investigated for preventing the progression of Covid-19 to severe pneumonia or ARDS.

From the FDA approval date, the trial will take place for 12 months. It will recruit a total of 60 participants across the EC-18 and placebo groups.

The trial’s primary endpoint is the proportion of patients alive and free of respiratory failure at day 28.

EC-18 was found to regulate neutrophil infiltration in preclinical studies, modulating the inflammatory cytokine and chemokine signalling found in severe Covid-19 patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The drug candidate was also observed to improve lung function, mitigate inflammation and fibrosis in various animal models of inflammatory diseases, including immune-mediated acute lung injury and pneumonia.

Enzychem Lifesciences CEO and chairman Ki Young Sohn said: “We are extremely pleased with the FDA’s decision and believe there is strong scientific rationale for the development of EC-18 to treat ARDS in Covid-19 patients.

“We look forward to advancing EC-18 as a potential new treatment option for patients with confirmed Covid-19, based on EC-18’s unique mechanism of action.”

EC-18 is obtained from Sika deer antler, which is known to function as Pattern Recognition Receptors (PRR) endocytic trafficking accelerator.

Dysregulation of the TLRs signaling pathway is involved in Covid-19-related ARDS.

EC-18’s mechanism is expected to help potentially treat chemoradiation induced oral mucositis (CRIOM), chemotherapy induced neutropenia (CIN) and acute radiation syndrome (ARS).